ADC Therapeutics (ADCT) Profit After Tax (2020 - 2026)

ADC Therapeutics (ADCT) has reported Profit After Tax for 7 consecutive years, with -$33.0 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax rose 14.6% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$137.0 million (up 9.38% YoY) and the FY2025 annual result came in at -$142.6 million, up 10.4% from the prior year.
• Profit After Tax eased to -$33.0 million in Q1 2026 per ADCT's latest filing, from -$6.4 million in the prior quarter.
• Over the last five years, Profit After Tax for ADCT reached as high as -$6.4 million in Q4 2025 and fell as low as -$86.9 million in Q4 2023.
• A 5-year average of -$43.2 million and a median of -$44.0 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax slumped 257.29% — and 2025, when it surged 80.01%.
• Year by year, Profit After Tax stood at -$25.5 million in 2022, then tumbled by 241.17% to -$86.9 million in 2023, then soared by 63.13% to -$32.1 million in 2024, then jumped by 80.01% to -$6.4 million in 2025, then sank by 414.4% to -$33.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$33.0 million, -$6.4 million, and -$41.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.